Mark W. Frohlich
Chief Executive Officer at Indapta Therapeutics, Inc.
Profile
Mark W.
Frohlich is currently the Chief Executive Officer & Director at Indapta Therapeutics, Inc., Director at BioEclipse Therapeutics, Inc., and Director at Neuvogen, Inc. Previously, he was the Vice President & Medical Director at Xcyte Therapies, Inc., Assistant Professor at The University of California, San Francisco, Chief Medical Officer & EVP-Research & Development at Dendreon Corp., and Executive Vice President-Portfolio Strategy at Juno Therapeutics, Inc. Frohlich received his undergraduate degree from Yale University in 1984 and his doctorate from Harvard Medical School in 1990.
Mark W. Frohlich active positions
| Companies | Position | Start |
|---|---|---|
BioEclipse Therapeutics, Inc.
 BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Director/Board Member | 24/06/2019 |
| Neuvogen, Inc. | Director/Board Member | 23/08/2021 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Chief Executive Officer | 10/02/2022 |
Former positions of Mark W. Frohlich
| Companies | Position | End |
|---|---|---|
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/09/2017 |
| DENDREON CORPORATION | Chief Tech/Sci/R&D Officer | 01/02/2014 |
| Xcyte Therapies, Inc. | Chief Tech/Sci/R&D Officer | 01/07/2005 |
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/2001 |
Training of Mark W. Frohlich
| Yale University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
| Xcyte Therapies, Inc. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
BioEclipse Therapeutics, Inc.
BioEclipse Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioEclipse Therapeutics, Inc. engages in the development of curative immune-oncology therapeutics for patient with cancer. Its patented immunotherapy is the CRX-100, which delivers potentially curative treatments to patients over a broad range of tumor type. The company was founded by Pamela R. Contag, Christopher Contag, and Robert Negrin and is headquartered in San Francisco, CA. | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Health Technology |
| Neuvogen, Inc. |
- Stock Market
- Insiders
- Mark W. Frohlich
